Syphilis Rapid Test Kit Market Size, Share and Trends Analysis, By Product Type (Treponemal Tests and Non-Treponemal Tests), By Technology (Lateral Flow Assay, Flow-through Assay, Agglutination Assay, and Molecular Diagnostics), By End-Use, By Distribution Channel, and By Region, Forecast 2025-2032

Syphilis Rapid Test Kit Market Overview and Key Insights:

The syphilis rapid test kit market size reached USD 986.5 million in 2024 and is expected to register a revenue CAGR of 6.8% during the forecast period. Treponema pallidum is the bacterium that causes syphilis, a sexually transmitted disease. Syphilis testing can be performed using a blood sample, a swab of fluid from a sore, or a spinal fluid sample.

Market Drivers:

Rising prevalence of syphilis is a key driver of revenue growth in the syphilis rapid test kit market. According to the Centre of Disease Control and Prevention (CDC), in 2023, nearly 2.4 million instances of syphilis, gonorrhoea, and chlamydia were detected and documented. This figure includes almost 209,000 instances of syphilis, 600,000 cases of gonorrhea, and 1.6 million cases of chlamydia. Importantly, the total tally includes 3,882 cases of congenital syphilis, including 279 stillbirths and neonatal/infant deaths. Between 2022 and 2023, the rate of syphilis (all stages) climbed 6.8% among women aged 15 to 44 years, with rates rising in 39 states and the District of Columbia.

The growing adoption of point-of-care and at-home testing drives market revenue during the forecast period. Clinicians can perform point-of-care (POC) tests during a clinical visit, enabling them to treat patients before they leave the clinic and thereby reducing the duration of infection. Sensitivity and specificity define the crucial properties of an ideal point-of-care test, especially in screening scenarios. Other critical characteristics of a POC test include cost, simplicity (automation), and turnaround time, which must be fast enough to influence treatment decisions.

On November 2024, NOWDiagnostics, Inc., a provider of over-the-counter (OTC) and point-of-care (POC) diagnostic tests, has announced that its First To Know Syphilis Test, a critical tool in syphilis prevention, is now available for purchase nationally. The first-of-its-kind, self-directed quick test gives at-home results in 15 minutes with as little as a drop of blood, giving people an accurate, simple, and discreet option to test for syphilis.

Market Opportunity:

Public health initiatives & preventive healthcare focus act as an opportunity for syphilis rapid test kit market. Syphilis is diagnosed based on a person’s clinical and sexual history, physical examination, laboratory tests, and, in rare cases, radiography, because symptoms are uncommon or difficult to detect. Rapid tests are also available and can deliver results in minutes, allowing for immediate treatment beginning. WHO has launched a global drive to eliminate congenital syphilis, as well as mother-to-child transmission of HIV and viral hepatitis B.

WHO has also developed syphilis treatment guidelines as well as guidelines for syphilis testing during pregnancy. These include the suggestion for the use of the dual HIV/syphilis test, which is inexpensive, effective, and cost-efficient in certain locations and circumstances.

Recent Trends:

Emerging trends include advancements in Immunochromatographic Assays (ICA), integration of digital and mobile technologies, and development of point-of-care molecular diagnostics.

Frequent syphilis testing, which allows for the quick and accurate detection of active infections and proper clinical therapy, is an important method for effectively preventing disease transmission. Conventional serological and molecular diagnostic methods are currently available for syphilis screening and diagnosis. Traditional serological testing for syphilis involves venipuncture to get whole blood for serum, while molecular diagnostic testing uses swabs of suspect sites/lesions, as well as blood, tissue, or cerebrospinal fluid (CSF), with various sensitivities.

Beyond detecting antibodies for the serological diagnosis of syphilis, developing rapid antigen POCTs offers two major advantages. First, rapid antigen detection tests can confirm the presence of T. pallidum and indicate current infection. Second, such tests enable earlier detection of syphilis, because the host typically takes several days to weeks to produce antibodies, and HIV-positive patients may delay seroconversion for months or may never undergo it.

Restraints & Challenges:

Most commercially available point-of-care (POC) syphilis platforms, including dual HIV/syphilis assays, detect treponemal antibodies. However, in environments with a high prevalence of previously treated syphilis, treponemal tests provide limited value, and clinicians must perform confirmatory testing to diagnose active infection and initiate treatment. Biomedical challenges in detecting and eliminating syphilis include the limited availability of diagnostic tests that support early diagnosis.

Current serologic tests are ineffective in the first several weeks of infection, creating a key gap during highly infectious early primary syphilis. Current treponemal tests, especially those used for fast testing, are positive for life. This makes previously treated cases and re-infection indistinguishable based just on treponemal tests, and interpretation is dependent on additional clinical information, which might be difficult to obtain.

Product Type Segment Insights and Analysis:

Based on the product type, the syphilis rapid test kit market is segmented into treponemal tests and non-treponemal tests.

Treponemal tests segment contributed the highest market share in 2024. It is further segmented into Immunochromatographic Assay (ICA), Enzyme Immunoassay (EIA), Chemiluminescence Immunoassay (CLIA), and Fluorescent Treponemal Antibody Absorption (FTA-ABS). Treponemal assays identify specific antibodies against T. pallidum proteins or peptides. Most treponemal assays detect IgG and IgM antibodies. However, several EIA assays specifically target IgM to support the diagnosis of very early syphilis.

Treponemal antibodies emerge earlier after infection than nontreponemal antibodies and often last a lifetime, even after effective therapy. Thus, treponemal test reactivity may be useful in early syphilis diagnosis when nontreponemal antibodies have not yet formed and tests are negative. Reactive treponemal tests may indicate active infection or previously treated or untreated infection, and clinicians must use them together with nontreponemal test results and clinical signs/symptoms to accurately diagnose syphilis.

On August 2024, QuidelOrtho Corporation has gained 510(k) approval from the United States Food and Drug Administration for its VITROS syphilis assay, which strengthens the company’s position as a leader in infectious disease diagnostics. This assay is designed to qualitatively determine total (IgG and IgM) antibodies to Treponema pallidum (TP)-specific antigens in human serum and plasma utilizing the automated VITROS 3600, 5600, and XT 7600 systems.

Technology Segment Insights and Analysis:

Based on the technology, the syphilis rapid test kit market is segmented into lateral flow assay, flow-through assay, agglutination assay, and molecular diagnostics.

Lateral flow assay segment contributed the largest market share in 2024. Lateral flow assays are a quick and convenient diagnostic test method for determining the presence or absence of a certain analyte, such as infectious microorganisms. They produce immediate outcomes, sometimes in as little as a few minutes. They do not require any specialized or expensive equipment to conduct the test or read the results. The tests provide results easily and inexpensively, usually within five to 30 minutes. Lateral flow devices combine antibodies, nitrocellulose membranes, and colored nanoparticles to generate visually interpretable data. Reader technology can also integrate with them to deliver rapid qualitative or quantitative results, improving accuracy.

On July 2025, BioLytical Laboratories Inc., a global leader in quick diagnostics, has obtained Health Canada approval for its iStatis Syphilis Antibody Test. The iStatis Syphilis Antibody Test is a lateral flow assay for detecting antibodies to Treponema pallidum, the bacteria that causes syphilis. The test is intended for use by healthcare professionals and aids in diagnosis using a simple fingerstick blood sample.

Geographical Outlook:

Syphilis rapid test kit market is strategically segmented by geography to provide a comprehensive understanding of regional market dynamic. Discover demand analysis, emerging trends, and growth opportunities shaping market performance across different region and countries.

North America Syphilis Rapid Test Kit Market:

North America is registered to have highest market share in syphilis rapid test kit market in 2024. This is mainly driven by rising prevalence of syphilis and technological advancements in syphilis rapid tests. According to the American Sexual Health Association, every year, over 20 million new STI cases are reported in the United States alone. Approximately half of these are in young persons aged 15 to 24 years. There were almost 207,255 syphilis cases in 2022. Most syphilis cases reported in the United States are in men, specifically gay, bisexual, and other men who have sex with men (MSM).

On July 2025, Labcorp, a global leader in creative and comprehensive laboratory services, announced a new collaboration with NOWDiagnostics (NOWDx), a pioneer in developing over-the-counter (OTC) and point-of-care (POC) diagnostic tests, to provide access to rapid syphilis testing. The firms will provide First to Know Syphilis Test kits at no cost to select community-based public health groups across the country. The First to Know Syphilis Test is the only over-the-counter syphilis test that yields accurate findings in 15 minutes.

Asia Pacific Syphilis Rapid Test Kit Market:

Asia Pacific is expected to register the fastest growth rate during the forecasted period, driven by rising prevalence of syphilis and adoption of point-of-care and at-home testing. According to the National Institute of Infectious Diseases, the total number of syphilis cases in Japan in 2024 was 14,663. Tokyo led the list with 3,703 cases, followed by 1,906 in Osaka, 880 in Fukuoka, 846 in Aichi, and 792 in Kanagawa. According to the Ministry of Health, Labor, and Welfare and other sources, the number of syphilis infections in Japan has been increasing since around 2011, but it has risen significantly in 2021. Since 2022, more than 10,000 instances have been documented per year.

On February 2023, LordsMed, Lord’s Mark Industries’ worldwide healthcare branch, has entered into a distribution agreement with Hindustan Antibiotics Limited (HAL), a major public-sector pharmaceuticals manufacturer. LordsMed just obtained ICMR approval to manufacture fast antigen test kits at its Vasai facility. LordsMed has used German technology to develop rapid test kits for malaria, cardiovascular illness, HIV, syphilis, hepatitis B surface antigen (HBsAg), dengue, chikungunya, typhoid, COVID, ovulation, and pregnancy.

Europe Syphilis Rapid Test Kit Market:

Europe is expected to have considerable market share in 2024. According to the European Centre for Disease Prevention and Control, in 2023, 29 EU/EEA member states reported 41,051 confirmed syphilis cases. those were seven times more likely than women to report syphilis, with the highest incidence among those aged 25 to 34. In 2023, eleven nations reported more than half of all cases of primary and/or secondary syphilis, compared to 10 in 2022. Overall, the trend in syphilis notifications rose between 2014 and 2023, owing primarily to an increase in the number of cases among MSM.

On January 2025, the London School of Hygiene and Tropical Medicine (LSHTM), Hospital for Tropical Diseases, University College London Hospital, has been awarded a prestigious Research Professorship worth approximately GBP 2 million by the National Institute of Health and Care Research (NIHR) to lead research into new tools to reduce syphilis cases in the UK. The NIHR Research Professorships plan seeks to promote and benefit health, public health, and care research leadership throughout the United Kingdom.

Competition Analysis:

The syphilis rapid test kit market is characterized by a fragmented structure, with several players competing across various segments and regions. list of major players included in the syphilis rapid test kit market report are:

• Abbott Laboratories
• CTK Biotech, Inc.
• Atlas Medical
• JAL Medical
• AccuBiotech Co. Ltd.
• Trivitron Healthcare
• AdvaCare Pharma
• Thermo Fisher Scientific
• Bio-Rad Laboratories, Inc.
• Becton, Dickinson and Company
• Vitrosens Biyoteknoloji A.Ş
• Roche Diagnostics
• Boen Healthcare Co., Ltd.
• Setia Scientific Solution
• Xiamen Boson Biotech Co., Ltd. 

Strategic Developments in Syphilis Rapid Test Kit Market:

• In July 2025, Abbott, a worldwide healthcare company, has announced the launch of a new World Health Organization (WHO)-approved triple test kit that enables African moms to test for HIV/AIDS, Hepatitis B, and Syphilis at the same time. According to Abbott, the breakthrough will boost efforts to eradicate these diseases by 2030. It is also projected to shorten patients’ stays in health facilities and increase the efficiency of healthcare delivery throughout Africa.
• In January 2024, the sexual wellness company Dame has released at-home diagnostics for sexually transmitted illnesses. The brand, known for its sexual wellness devices and topicals, is expanding into the health arena with four STI kits, which are accessible on the company’s website. After purchasing the kits, consumers will do the test at home, submit it to a lab, and obtain simulated results.
• In August 2023, iHealth Labs, Inc., a digital health firm and the top provider of at-home COVID tests in the United States, has announced the availability of its Home Collection Kit for HIV and syphilis testing. The FDA-approved solution allows anybody over the age of 18 to collect a blood sample to test for HIV (I, II, P24 antigen) and syphilis in the comfort of their own home, mail it to the lab with a prepaid overnight label, and obtain reliable and confidential results in as little as two days.

Key Advantages for Stakeholders:

Navistrat Analytics’ industry report provides an in-depth quantitative analysis of various market segments, historical and current trends, market forecasts, and dynamics within the global market. The historical years covered in this report are 2022 to 2023, with 2024 serving as the base year for market size calculations. The forecast period extends from 2025 to 2032.

The report includes an executive summary and a comprehensive overview of market drivers, restraints, opportunities, and challenges (DROC), along with insights into regulatory standards. It features detailed analyses such as PORTER’s Five Forces, SWOT, and PESTLE, as well as assessments of technological trends and the competitive landscape.

PORTER’s Five Forces analysis helps stakeholders evaluate the impact of new entrants, competitive rivalry, supplier power, buyer power, and substitution threats, enabling them to assess the level of competition and the attractiveness of the global market. The competitive landscape provides stakeholders with a clear understanding of the current market positions of key players, offering valuable insights into their competitive environment.

Scope And Key Highlights Of The Syphilis Rapid Test Kit Market Report:

The Syphilis Rapid Test Kit market report offers a detailed analysis of market size, including historical revenue (in USD Million) data for 2022-2023 and revenue forecasts for 2025-2032 across the following segments:

• Product Type Outlook (Revenue, USD Million; 2022-2032)
  • Treponemal Tests
    • Immunochromatographic Assay (ICA)
    • Enzyme Immunoassay (EIA)
    • Chemiluminescence Immunoassay (CLIA)
    • Fluorescent Treponemal Antibody Absorption (FTA-ABS)
  • Non-Treponemal Tests
    • Rapid Plasma Reagin (RPR)
    • Venereal Disease Research Laboratory (VDRL)
    • Toluidine Red Unheated Serum Test (TRUST)

• Technology Outlook (Revenue, USD Million; 2022-2032)
  • Lateral Flow Assay
  • Flow-through Assay
  • Agglutination Assay
  • Molecular Diagnostics

• End-Use Outlook (Revenue, USD Million; 2022-2032)
  • Hospitals and Clinics
  • Diagnostic Laboratories
  • Point-of-Care Settings
  • Others

• Distribution Channel Outlook (Revenue, USD Million; 2022-2032)
  • Online
  • Offline
    • Direct
    • Retail Pharmacies/Distributors

• Regional Outlook (Revenue, USD Million; 2022-2032)
  • North America
    • U.S.
    • Canada
    • Mexico
  • Europe
    • Germany
    • France
    • U.K.
    • Italy
    • Spain
    • Benelux
    • Nordic Countries
    • Rest of Europe
  • Asia Pacific
    • China
    • India
    • Japan
    • South Korea
    • Oceania
    • ASEAN Countries
    • Rest of APAC
  • Latin America
    • Brazil
    • Rest of LATAM
  • Middle East & Africa
    • GCC Countries
    • South Africa
    • Israel
    • Turkey
    • Rest of MEA

Frequently Asked Questions (FAQ) about the Syphilis Rapid Test Kit market report